XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
  AIDS
  Influenza
  MRSA
  Tuberculosis
  Shigella
  HCV
  SARS
  Ebola
  Dengue
  Malaria
  Pertussis
  Mumps
  Prion Diseases
  Small Pox
  Anthrax
  Leishmaniasis
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Anthrax Channel
subscribe to Anthrax newsletter

Latest Research : Infectious Diseases : Anthrax

   DISCUSS   |   EMAIL   |   PRINT
PlyPH protein kills anthrax bacteria by exploding their cell walls
Apr 22, 2006, 17:43, Reviewed by: Dr. Sanjukta Acharya

“PlyPH works in an extremely wide pH range, from as low as four to as high as eight. I don’t know of any other lytic enzyme that has such a broad range of activity.”


 
Not all biological weapons are created equal. They are separated into categories A through C, category A biological agents being the scariest: They are easy to spread, kill effectively and call for special actions by the pubic health system. One of these worrisome organisms is anthrax, which has already received its fair share of media attention. But work in Vince Fischetti’s laboratory at Rockefeller University suggests that a newly discovered protein could be used to fight anthrax infections and even decontaminate areas in which anthrax spores have been released.

“Anthrax is the most efficient biowarfare agent. Its spores are stable and easy to produce, and once someone inhales them, there is only a 48-hour window when antibiotics can be used,” says Fischetti. “We’ve found a new protein that could both potentially expand that treatment window and be used as a large-scale decontaminant of anthrax spores.” Because anthrax spores are resistant to most of the chemicals that emergency workers rely on to sterilize contaminated areas, a solution based on the protein would be a powerful tool for cleaning up after an anthrax attack.

All bacteria, anthrax included, have natural predators called bacteriophage. Just as viruses infect people, bacteriophage infect bacteria, reproduce, and then kill their host cell by bursting out to find their next target. The bacteriophage use special proteins, called lysins, to bore holes in the bacteria, causing them to literally explode. Fischetti and colleagues identified one of these lysins, called PlyG, in 2004, and showed that it could be used to help treat animals and humans infected by anthrax. Now, they have identified a second lysin, which they have named PlyPH, with special properties that make it not only a good therapeutic agent, but also useful for large-scale decontamination of areas like buildings and military equipment.

The new protein has several advantages. Most lysins, including PlyG, are only active in a very specific pH range of six to seven, so that they work very effectively in our bloodstream, but may not useful in many environmental conditions. “PlyPH works in an extremely wide pH range, from as low as four to as high as eight,” says Fischetti. “I don’t know of any other lytic enzyme that has such a broad range of activity.”

In addition, PlyPH, like PlyG, is highly specific in terms of the types of bacteria it affects. When Fischetti and colleagues added PlyPH to different bacterial species, only the anthrax bacteria were killed. This is a great benefit over antibiotics, which kill many different kinds of bacteria, including many helpful species. Because it is so specific, the chances of anthrax becoming resistant to PlyPH, as it is to many of the antibiotics currently available to treat it, are extremely low.

“We have never seen bacterial resistance to a lysin,” says Fischetti. “PlyPH and PlyG are probably the most specific lysins we, or anyone, has ever identified — they only kill anthrax and its very close relatives. This feature, and the wide pH range offered by PlyPH, is why we think it could be used as an environmental decontaminant.”

Fischetti hopes to combine PlyPH with a non-toxic aqueous substance developed by a group in California that will germinate any anthrax spores it comes in contact with. As the spores germinate, the PlyPH protein will kill them, usually in a matter of minutes. The combined solution could be used in buildings, on transportation equipment, on clothing, even on skin, providing a safe, easy way to fight the spread of anthrax in the event of a mass release.
 

- Vince Fischetti’s laboratory at Rockefeller University
 

Journal of Bacteriology 188(7): 2711-2714 (April 2006)

 
Subscribe to Anthrax Newsletter
E-mail Address:

 



Related Anthrax News

Monoclonal antibody recognizes a specific sugar on the surface of anthrax bacteria spores
Scientists design functionalized liposome - a potent anthrax toxin inhibitor
PlyPH protein kills anthrax bacteria by exploding their cell walls
Surprising new insights about the acid pH levels required for anthrax toxin
Diagnostic method for identifying Bacillus anthracis receives FDA approval
Protective Antigen Ion Channel Asymmetric Blockade To Detect Anthrax Infection
ABthrax(TM) Safe and Effective against Anthrax
DNI - Newly Identified Inhibitor of Anthrax Toxin May Contribute to Postexposure Therapy


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us